Cecilia Daun Wennborg was appointed to the board of Oncopeptides in 2017.
Cecilia has 14 years of experience from board positions in listed companies and 20 years of experience from operational positions in the insurance, bank, care and healthcare sectors, inter alia as CFO and CEO of Skandia Link, Head of Skandia Sverige, CFO of Carema Vård & Omsorg AB and Ambea AB, CEO of Carema Vård & Omsorg AB and deputy CEO of Ambea AB.
She has been an ordinary board member and chairman of the board of directors in Randstad AB (previously Proffice Aktiebolag), board member in Carnegie Fonder AB, Eniro AB, Ikano Bank AB (publ), Aktiebolaget Svensk Bilprovning and Kvinvest AB.
Cecilia holds a MSc in Business and Economics from Stockholm University.
Board Committees: Chairman of the Audit Committee
Holdings in Oncopeptides: 11,800 shares and 12,977 Share Awards**
Other current assignments: Member of the board of directors in Getinge AB, Bravida Holding AB, ICA Gruppen AB, Loomis AB, Atvexa AB, Insamlingsstiftelsen Oxfam Sverige, Sophiahemmet AB and the non-profit organisation Sophiahemmet, Hotel Diplomat AB and CDW Konsult AB. Member of the Swedish Securities Council.
Independent in relation to the Company and its management and in relation to major shareholders.